Treatment Duration of Treatment Progression Free Survival (months) Treatment Response
CVP 6 cycles 16 Partial response
Rituximab (start 8/9/2001) 8 cycles 31 Complete response
Rituximab (start 4/2004) 5 cycles 15 Partial response
Radiation Therapy 2000 cGy in 10 fractions 1 Stable disease
Everolimus trial (start 1/2007) 12 months 12 Stable disease
Lenalidomide start 9/27/2010) 5 months 5 Partial response
Rituximab (start 2/2011) 8 cycles 11 Stable disease
Lenalidomide (start 1/2012) 28 months 28 Complete response
PI3K delta Inhibitor trial (6/2014) 6 months 6 Partial response
Gemcitabine and Oxaliplatin (start 12/30/2014) 7 cycles 19 Partial response
Axicabtagene ciloleucel (9/2018) N/A 20 Complete response
Axicabtagene ciloleucel (6/2020) N/A 2 Partial response
BCL-2 inhibitor trial 2 weeks 0 No response
Obinutuzumab and Lenalidomide 5 cycles Ongoing (>6) Complete response
Lenalidomide maintenance Ongoing Ongoing (>6) Complete response